FDA Needs External Board To Boost Industry Input – von Eschenbach
This article was originally published in The Tan Sheet
Executive Summary
At the Forbes health care summit, thought leaders pitched ways to improve FDA and the processes of making medical innovations available. FDA Commissioner Hamburg cited the agency’s openness to biomarkers, innovative clinical trial designs and mandatory recall authority.